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ABSTRACT
Objectives: To assess the diagnostic value of cervical cytology and HPV HR DNA testing for the diagnosis of low grade and 
high-grade squamous intraepithelial lesions across different age groups.
Material and methods: The study included 1103 patients, age 25–70 years. All patients underwent in-depth diagnostic 
tests following either an abnormal Pap test result or a clinically suspicious cervical lesion. In all women the following 
examinations were performed: a molecular test detecting 14 high-risk types of HPV, a colposcopy examination, as well as 
directed-biopsy of the cervix. The studied population was subdivided into four age groups. 
Results: It was observed that the percentage of high grade squamous intraepithelial lesions (HSIL) and cancers increased with 
women’s age. Sensitivity of both methods for detecting high-grade squamous intraepithelial lesions was highest for women 
aged 40–49 years. Sensitivity values of HPV testing was higher than that of cervical cytology among women under age 50.
Conclusions: Specificity of HPV testing increased significantly with age of women and was several fold higher across all 
age groups than the specificity of cervical cytology. 
Key words: Pap test, HPV testing, low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial 
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INTRODUCTION
Retrospective analysis of the incidence rate of cervical 
cancer in Poland shows, that the epidemiological situation 
has improved over the last thirty years, especially during the 
last decade. Nevertheless, it is estimated that over 3000 new 
cervical cancers are being diagnosed each year and over half 
of the women die from the disease [1]. Cervical intraepitheli-
al neoplasia can effectively undergo conservative treatment, 
which is of a special value for women of reproductive age. 
Since mid-nineties the incidence and mortality rates of 
cervical cancer have decreased in Poland [2]. After 2005, the 
introduction of the Screening Program for the Prophylaxis 
and Early Diagnosis of Cervical Cancer laid the groundwork 
for dynamic changes. Cytology-based screening was indi-
cated for women aged 25–59 years. 
The primary purpose of cervical screening programs is to 
diagnose precancerous lesions of the cervix which, accord-
ing to FIGO of 1988, were classified as either low- (CIN 1), 
mid- (CIN 2) or high-grade cervical intraepithelial neoplasia 
(CIN 3). Cervical intraepithelial neoplasia are defined by both 
morphological criteria and architectural features of epithe-
lial layers. Until recently, these lesions — CIN 2 and CIN 3, 
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were defined as true precancerous lesions of the cervix. In 
2012, the College of American Pathologists together with 
the American Society of Colposcopy and Cervical Pathology 
initiated a project, which introduced new nomenclature of 
HPV-related squamous lesions of anogenital region (LAST 
— The Lower Anogenital Squamous Terminology Project). 
Since the diagnosis of CIN 2 is characterized by low repeti-
tion and a high percentage of these lesions are reclassifi-
cation as either CIN 1 or CIN 3, the LAST Project supports 
a two-tiered nomenclature of squamous intraepithelial le-
sions, distinguishing low-grade squamous intraepithelial 
lesions (LSIL) and high-grade squamous intraepithelial le-
sions (HSIL). Lesions previously classified as CIN 2 should 
be tested immunohistochemically in order to detect the 
expression of p16 protein. Lesions negative for p16 should 
be classified as LSIL, while lesions positive for p16 should 
be classified as HSIL [3, 4].
For many years, there has been an ongoing debate on 
the improvement of diagnostic tools to detect precancerous 
states of the cervix. Future research should focus on the age 
at which screening should be initiated, as well as the optimal 
age-specific diagnostic test. 
Beyond reasonable doubt it is known, that the use of 
cytology-based screening in the prophylaxis of cervical 
cancer is insufficient. Introduction of cervical cytology as 
the basis of cervical cancer screening during the second 
half of the twentieth century, contributed to a significant 
decline in the incidence and mortality rates due to cervical 
cancer world-wide. Nevertheless, despite the introduction 
of numerous modifications, sensitivity of this method in the 
diagnosis of high-grade squamous intraepithelial lesions 
(HSIL) is unsatisfying. Currently there is no question that 
there is a cause and effect relationship between persistent 
infection with high oncogenic types of HPV and the devel-
opment of cervical intraepithelial neoplasia and its progres-
sion to invasive cancer. The development of knowledge of 
human papillomavirus and process of carcinogenesis lead 
to the incorporation of molecular tests, which can detect 
the DNA of high oncogenic types of HPV into diagnostic 
methods. Currently, there is an ongoing debate on the 
role of molecular diagnostic tests in the screening pro-
grams. Many authors underline that HPV testing is more 
sensitive for squamous intraepithelial lesions than cervical 
cytology. The American College of Obstetrics and Gyne-
cology first incorporated HPV testing in their guidelines 
in 2003. Since 2012, HPV testing is highly recommended 
along with the routine cervical cytology for women age 
30–65 years [5].
OBJECTIVES
The purpose of the study was to compare the diagnostic 
value of cervical cytology and HPV HR DNA testing for the 
diagnosis of low grade and high-grade squamous intraepi-
thelial lesions across different age groups.
MATERIAL AND METHODS
Between 2011 and 2014, 1103 patients aged 25 and 
older underwent in-depth diagnostics at the Laboratory 
of Cervical Pathophysiology, Gynecology and Obstetrics 
Clinical Hospital, Karol Marcinkowski University of Medical 
Sciences, Poznan. Women were referred to the Laboratory 
because of either an abnormal Pap test result or a clinically 
suspicious cervical lesion. According to the Bethesda System 
(TBS), abnormal results include ASC-US, ASC-H, LSIL, HSIL, 
AGC or cancer cells. Incorrect cytologic results including LSIL 
and ASCUS were indication for directed punch biopsy in 
case of suspicious lesions presented in colposcopy examina-
tion. In case of AGC diagnosis, the colposcopy examination 
with punch biopsy of suspicious lesions was performed 
together with the curettage of endocervix and endome-
trium. The study excluded pregnant women and underage 
patients. The opinion of a Bioethical Committee has not 
been required to perform the study.
The number of patients with a particular cytological 
diagnosis is presented in Table 1. 
The following tests were performed in each patient:
 Ū Pap smear,
 Ū HPV test,
 Ū colposcopy examination,
 Ū directed-biopsy of the cervix,
 Ū histopathological evaluation.
Pap smear
The cytology was collected using a cyto-brush and 
smeared onto a microscope slide. Then, the cells were fixed 
and subsequently stained with haematoxylin, Orange G 
stain, as well as Eosin Azure. After staining and fixing the 
specimen, it was coated with xylene and Canada balsam. 
Smears were evaluated by senior cytologists and reported 
using currently recommended Bethesda System (TBS). All 
abnormal Pap test results were reevaluated by pathologists 
at the Laboratory of Pathophysiology of the Cervix, Gyne-
Table 1. Number of patients with a particular cytological diagnosis
Pap test result Normal ASC-US ASC-H LSIL HSIL AGC Suspicion of cancer 
Number of patients 137 324 47 402 177 7 9
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cology and Obstetrics Clinical Hospital, Karol Marcinkowski 
University of Medical Sciences, Poznan.
HPV test
A material was collected from cervix using cyto-brush, 
and subsequently it was placed in a buffer, ThinPrep Preserv-
Cyt Solution. For detection of DNA HR HPV types, we used 
a molecular test known as the Cobas HPV test, Roche Diag-
nostics. This test, based on real-time PCR method, identifies 
14 most commonly occurring high-risk, oncogenic, types of 
HPV in vitro with genotyping for high risk HPV types 16 and 
18. Surveillance of the cells is guaranteed by simultaneous 
PCR amplification of the beta-globin HPV DNA. 
The colposcopy examination
The colposcopy examination — conducted at the Labo-
ratory of Cervical Pathophysiology — was performed using 
a stereoscopic colposcope, Olympus OCS-500. Visualization 
of the transformation zone was the basis for classification 
of the colposcopic image as satisfactory. Each time, 3% 
acetic acid and Schiller’s test using a Lugol’s liquid was 
performed. Colposcopic images were evaluated using Reid’s 
Colposcopic Index, which assesses lesion margin, color of 
acetowhitening, blood vessels and iodine staining. 
Directed-biopsy of the cervix
In each patient, qualified for the study, a directed-biopsy 
of a clinically suspicious lesion and endocervical curettage 
were performed. Colposcopic image helped to identify ab-
normal cervical areas, which warranted biopsy. Sampled 
tissue, fixed in a buffer of formalin, after dehydration was 
embedded in paraffin blocks, and subsequently stained with 
hematoxylin and eosin. All specimens were subjected to 
a blinded independent evaluation of the Pathomorphologi-
cal Laboratory team at Gynecology and Obstetrics Clinical 
Hospital, Karol Marcinkowski University of Medical Sciences, 
Poznan.
Statistical methods
In terms of diagnostic methods (cytodiagnostics and 
molecular test for the presence of DNA HR types HPV) we 
determined sample size with values of true positive, true 
negative, false positive and false negative. Based on these 
values, the sensitivity, specificity, positive and negative pre-
dictive value with 95% confidence intervals were estimated. 
The sensitivity and specificity of cytology and HPV were 
compared by McNemar’s test while the PPV and NPV were 
compared by test for the two fractions. Four age groups were 
determined, in which these indicators were also calculated. 
It was estimated whether increasing age resulted in higher 
rates of sensitivity, specificity, PPV and NPV by Chi2 test for 
the trend. Statistical hypotheses were verified at the sig-
nificance level α = 0.05. Calculations were performed using 
the statistical package StatSoft, Inc. (2011) STATISTICA (data 
analysis software system), ver. 10 and MedCalc ver. 13,0,6,0.
RESULTS
The study included 1103 women. Pathomorphological re-
sults revealed the presence of high-grade squamous intraepi-
thelial lesions — HSIL in 217 patients (19.6%) and low-grade 
squamous intraepithelial lesions — LSIL in 169 patients 
(15.3%). 13 cases of carcinoma planoepitheliale and 2 cases of 
adenocarcinoma were revealed which collectively constituted 
1.3% of the studied population. 702 women (63.6%) did not 
have a pathologically proven neoplastic lesions.
For the purpose of this study women were subdivided 
into four age groups:
 Ū age 25–29 years — 306 women (27.7%),
 Ū age 30–39 years — 455 women (41.2%),
 Ū age 40–49 years — 194 women (17.5%),
 Ū 50+ age group — 148 women (13.4%).
The population of individual subgroups is presented 
in Figure 1. 
HSIL type of changes was most prevalent in all age 
groups. Over half of the patients aged 25–29 years and 
30–39 years were diagnosed with HSIL type of changes 
(61.2% and 53.4% respectively). In the remaining subgroups 
HSIL also constituted the most common diagnosis: 45.4% 
of patients aged 40–49 years and 46.6% of patients over 
the age of 50. All cases of adenocarcinoma and 84.6% of 
carcinoma planoepitheliale were diagnosed in women over 
the age of 40 years (Fig. 2). 
Sensitivity of the Pap test and HPV test was calculated in 
each age group. The sensitivity of both tests for HSIL type of 
changes was the highest for women aged 40–49 years: cervi-
cal cytology 91.4% and HPV testing 97.1%. For women under 
the age of 50, sensitivity of HPV testing was significantly 
higher than that of cervical cytology and clearly increased 
with the age of our patients. In the 50+ age group, sensitivity 
25–29 years
306
30–39 years
455
40–49 years
194
Above 50 years
14827.7%
41.2%
17.5%
13.4%
Age
Figure 1. Population of women in each age group
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of the Pap testing was 4.6% higher than that of the HPV test-
ing. The results are presented in both Table 2 and Figure 3.
Sensitivity values of both diagnostic tests for low-grade 
and high-grade squamous intraepithelial lesions collectively 
(LSIL + HSIL) again were highest in women aged 40–49 years 
(90.9% for HPV testing, 93.9% for the Pap testing). The dif-
ference between sensitivity values of both tests faded in 
women under 50 years of age in favor of HPV testing, while in 
women aged 40–49 years sensitivity of high-risk HPV testing 
was 3% lower than that of the Pap testing. Meanwhile, in the 
50+ age group, as in the case of HSIL type of changes alone, 
sensitivity of cervical cytology was higher than that of HPV 
test. In the 50+ age group sensitivity of cervical cytology 
was 13.3% higher than that of molecular test (Tab. 3, Fig. 4).
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49
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37.9%
61.2%
46.0%
53.4%
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0
1
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45.4%
7.5%
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0
5
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31
26.6%
46.6%
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Figure 2. The incidence of histopathologic diagnoses in certain age groups
Table 2. Sensitivity of Pap testing and HPV testing for HSIL across 
four age groups (%)
Age group 25–29 30–39 40–49 > 50
Group size N = 306 N = 455 N = 194 N = 148
Pap test 87.5 86.3 91.4 90.9
HPV test 93.7 95.7 97.1 86.3
25–29 years 30–39 years 40–49 years Above 50 years
Pap smear
HPV test
100
95
90
85
80
75
Age
Figure 3. Sensitivity of Pap testing and HPV testing for HSIL across 
four age groups
25–29 years 30–39 years 40–49 years Above 50 years
Pap smear
HPV test
100
95
90
85
80
75
Age
Figure 4. Sensitivity of Pap testing and HPV testing for LSIL + HSIL 
collectively across four age groups
Table 3. Sensitivity of Pap testing and HPV testing for LSIL + HSIL 
type of changes collectively across four age groups (%)
Age group 25–29 30–39 40–49 > 50
Group size N = 306 N = 455 N = 194 N = 148
Pap test 89.9 90.3 93.9 93.3
HPV test 90.6 93.7 90.9 80.0
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Figures 5 and 6 show specificities of each method for 
HSIL and LSIL + HSIL, respectively. Specificity of a molecular 
test increases with the increasing age of women. Pap test 
specificity is, in both cases, smaller than that of HPV test. 
Furthermore, it is independent of patients’ age (Tab. 4, 5).
DISCUSSION
The analysis of the age at diagnosis of cervical cancer 
in Poland, based on the Countries Cancer Register, revealed 
an increase in the number of observed cases at the age of 
30 and older. The risk of cervical cancer increases with age, 
but mostly (about 60%) concerns women age 45–64 years 
and then gradually decreases [6]. Intensification of preven-
tive actions should focus on population of women aged 
30–60 years. In the course of our study all cancer cases were 
diagnosed in women over the age of 40. Along with increas-
ing age the percentage of low-grade squamous intraepithe-
lial lesions (LSIL) decreased, while the percentage of more 
advanced lesions like high-grade squamous intraepithelial 
lesions (LSIL) and cancers increased. 
Numerous studies have shown that diagnostic test de-
tecting the DNA of HR HPV types presents higher sensitivity 
and negative predictive value, compared to cervical cyto- 
logy. A study conducted in Canada, analyzing ten thousand 
women, revealed that sensitivity of HPV testing for HSIL 
is 94.6%, while sensitivity of cervical cytology is merely 
55.4% [7]. Some reports show that sensitivity of Pap test-
ing increases with age [8]. According to Nanda et al., the 
range of sensitivity values of cervical cytology vary widely 
(30–87%) [9]. Our study confirms that the molecular test 
is characterized by higher sensitivity, when compared to 
cervical cytology, for high-grade squamous intraepithe-
lial lesions. Nevertheless, considering both low-grade and 
high-grade squamous intraepithelial lesions, sensitivity of 
both methods is comparable. Furthermore, it was noted that 
sensitivity value of HPV testing gradually increases with age 
and reaches a peak in women aged 40–49 years. Whereas 
a relationship between increasing sensitivity of cervical 
cytology and age of our patients was not observed.
Diagnostic test with high specificity is useful for ruling out 
disease in healthy individuals. In the present study, in 63.6% of 
women who underwent in-depth diagnostic tests, mainly for 
epithelial cell abnormalities, the lesion of cervical epithelium 
have not been histologically confirmed. High rate of false 
positives can lead to unnecessary diagnostic and therapeutic 
interventions, and therefore increase the costs. Specificity for 
HSIL type of changes ranged between 8.7% and 13.8% and did 
not correlate with patients’ age. Fundamentally different re-
sults were observed in the case of HPV test. Specificity of HPV 
test for HSIL as well as for HSIL plus LSIL collectively, gradually 
increased with age. In 50+ age group, specificity of molecular 
test was over 80%, which seems to be the logical consequence 
of the natural course of HPV infection. Human papilloma-
virus infection is widely spread among young women. It is 
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N = 455
30–39 years
N = 194
40–49 years
N = 148
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Pap smear
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Figure 5. Specificity of Pap testing and HPV testing for HSIL across 
four age groups
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Figure 6. Specificity of Pap testing and HPV testing for LSIL + HSIL 
collectively across four age groups
Table 4. Specificity of Pap testing and HPV testing for HSIL across 
four age groups (%)
Age group 25–29 30–39 40–49 > 50
Group size N = 306 N = 455 N = 194 N = 148
Pap test 11.9 13.8 13.2 8.7
HPV test 34.9 49.4 64.7 80.9
Table 5. Specificity of Pap testing and HPV testing for LSIL + HSIL 
collectively across four age groups (%)
Age group 25–29 30–39 40–49 > 50
Group size N = 306 N = 455 N = 194 N = 148
Pap test 13.5 16.4 15.6 9.3
HPV test 40.6 61.2 76.5 83.8
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estimated that HPV infection concerns 24% of women aged 
25 and younger while in women aged 35–44 years it is only 
9% [10]. Beyond that, in teenagers and women under 34 years 
of age, over 80% of precancerous lesions of the cervix regress 
spontaneously without treatment. In women aged 35 and 
above, 40% regress, while the remaining 60% progress to 
more advanced disease [11]. This data explain the low speci-
ficity of tests among younger age groups. Simultaneously, 
along with the increasing age, the risk of persistent infection 
increases, meanwhile the prevalence of the virus among the 
population decreases [12, 13]. In medical and economic terms, 
it seems justifiable to introduce HPV tests into screening not 
earlier than in women aged 30–35. 
CONCLUSIONS
1. Sensitivity values of cervical cytology and molecular test 
for high-grade squamous intraepithelial lesions were 
highest in women aged 40–49 years. 
2. Sensitivity of HPV testing was higher than that of cervical 
cytology among women under age 50. 
3. Specificity of HPV test increased with age and was 
several-fold higher than specificity of cervical cytology 
across all age groups.
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